The effect of primary urological cancers on survival in men with secondary prostate cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: The prostate, 2021, online version before inclusion in an issue, doi:10.1002/pros.24209, ISSN 1097-0045
- Ereignis
-
Veröffentlichung
- (wo)
-
Frankfurt am Main
- (wer)
-
Universitätsbibliothek Johann Christian Senckenberg
- (wann)
-
2021
- Urheber
-
Wenzel, Mike
Würnschimmel, Christoph
Nocera, Luigi
Collà Ruvolo, Claudia
Tian, Zhe
Saad, Fred
Briganti, Alberto
Tilki, Derya
Graefen, Markus
Roos, Frederik
Mandel, Philipp
Chun, Felix
Karakiewicz, Pierre I.
- URN
-
urn:nbn:de:hebis:30:3-626482
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wenzel, Mike
- Würnschimmel, Christoph
- Nocera, Luigi
- Collà Ruvolo, Claudia
- Tian, Zhe
- Saad, Fred
- Briganti, Alberto
- Tilki, Derya
- Graefen, Markus
- Roos, Frederik
- Mandel, Philipp
- Chun, Felix
- Karakiewicz, Pierre I.
- Universitätsbibliothek Johann Christian Senckenberg
Entstanden
- 2021
Ähnliche Objekte (12)
The effect of primary urological cancers on survival in men with secondary prostate cancer
Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer
Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores
Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities
Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients
Entstehung von oxidativen Stressmarkern in DNA und RNA nach der Behandlung mit den Hormonen Angiotensin II und Aldosteron in vitro und in vivo : Vergleich von drei Analysemethoden zum Nachweis von 8-Oxo-2'-desoxyguanosin in LLC-PK1-Zellen
Twenty-year trends in prostate cancer stage and grade migration in a large contemporary german radical prostatectomy cohort
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer
The effect of primary urological cancers on survival in men with secondary prostate cancer
Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer
Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores
Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities
Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients
Entstehung von oxidativen Stressmarkern in DNA und RNA nach der Behandlung mit den Hormonen Angiotensin II und Aldosteron in vitro und in vivo : Vergleich von drei Analysemethoden zum Nachweis von 8-Oxo-2'-desoxyguanosin in LLC-PK1-Zellen
Twenty-year trends in prostate cancer stage and grade migration in a large contemporary german radical prostatectomy cohort
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer
The effect of primary urological cancers on survival in men with secondary prostate cancer
Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer
Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores
Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities
Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients
Entstehung von oxidativen Stressmarkern in DNA und RNA nach der Behandlung mit den Hormonen Angiotensin II und Aldosteron in vitro und in vivo : Vergleich von drei Analysemethoden zum Nachweis von 8-Oxo-2'-desoxyguanosin in LLC-PK1-Zellen
Twenty-year trends in prostate cancer stage and grade migration in a large contemporary german radical prostatectomy cohort
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis